Aims: To conduct a systematic review and meta-analysis with the aim of providing robust estimates of the association between diabetes and long-term (≥1 year) mortality after acute myocardial infarction (AMI).
| INTRODUCTION
Diabetes is a major risk factor for cardiovascular disease, conferring an approximate 2-fold increase in the risk of acute myocardial infarction (AMI). 1 Diabetes and impaired glucose tolerance are very common among people with AMI, being observed in almost two thirds of patients at presentation, and are associated with a 2-fold higher mortality rate than in those with normoglycaemia. 1 Furthermore, the recent trends in improved survival after AMI, attributed to improved acute care and better use of preventative strategies, are less obvious among those with diabetes than in those without. 2 While many studies have examined survival after AMI among individuals with diabetes, the focus has been on short-term rather than long-term mortality. Furthermore, even those studies which assessed long-term mortality after AMI have reported inconsistent findings. [3] [4] [5] Two meta-analyses have been performed to date and, whilst informative, their findings may not provide reliable risk estimates in broader populations. 6, 7 The first study included only randomized controlled trials (RCTs) and reported information on 11 trials, including 62 036 individuals from the Thrombolysis in Myocardial Infarction (TIMI) database, and therefore excluded a large number of global trials whilst assessing mortality only as far as 1 year after acute coronary syndrome (ACS). 6 The other major meta-analysis included a select group of patients with ST elevation myocardial infarction (STEMI), treated with primary percutaneous intervention (PCI) and stent insertion, from 11 studies including 6298 patients. 7 To provide more reliable evidence than hitherto possible on the impact of diabetes on long-term mortality after AMI, we conducted a systematic review and meta-analysis of all available data in the reperfusion era and compared the all-cause, long-term mortality (1 year and longer)
among those with and without diabetes after hospitalization for AMI.
| MATERIALS AND METHODS

| Data sources and searches
The Medline, EMBASE and Web of Science databases were searched for articles in English. Search strategies were tailored to the relevant databases, and, in addition, reference lists were searched for potentially eligible articles. We used keywords and Medical Subject Headings (MeSH) related to AMI, ACS, diabetes mellitus, hyperglycaemia, blood glucose, impaired glucose regulation, mortality, morbidity, prognosis, course, outcomes and follow-up, aiming at identifying full-text, published papers. Further details of the search strategies are included in Methods S1 and Table S1 , File S1.
| Study selection
Each title and abstract was independently scrutinized by 2 authors for suitability. Identified papers were independently assessed by each author to assess suitability for inclusion. In order to include patients with AMI who were likely to have been treated by modern reperfusion or early invasive strategies, we rationalized our inclusion criteria as follows: (1) we included articles published after January 1985 until July 2016 (Methods S2, 8, 9 File S1); (2) reporting studies had to have commenced recruitment after January 1985; (3) studies where recruitment commenced before 1985 but continued after 1985 were only included if 50% of the recruitment period occurred after January 1985. We excluded studies where: (1) there was <1 year of followup; (2) there were <100 total participants; (3) the design was casecontrol; (4) individuals were systematically screened during the index AMI admission for identifying newly diagnosed diabetes; (5) individuals were diagnosed as having diabetes based solely on elevated glucose levels >11.0 mmol/mol at index admission; (6) the report focused on mortality in relation to blood glucose levels without reporting mortality for those with and without diabetes; and (7) reporting was only on subgroups which could not be generalized, for example, reports restricted to those with left ventricular failure or cardiogenic shock. Where studies had a mixed cohort of patients with AMI and unstable angina, data related to only AMI (STEMI and non-STEMI) were extracted. Because this was an analysis of AMI requiring hospitalization, out-of-hospital deaths as a presentation of index AMI were excluded. In articles reporting more than one cohort, information on each study was extracted separately and in case of multiple reports of the same study, the data from the most informative article were used. 10 and percentages. The quality of the studies was assessed by 2 independent reviewers using the US Preventive Service Task Force (USPSTF) quality rating criteria for the RCTs and cohort studies, and studies were categorized into good-, fair-and poorquality groups (Box S1, File S1). 11 Disagreements related to any aspects of the review, selection, data extraction or quality assessment were resolved through discussion.
| Data extraction and quality assessment
| Data synthesis and analyses
We performed analysis in 2 different ways, producing 2 sets of outcome data. First, for all selected studies, risk ratios were derived from the reported number of patients and the number of deaths in diabetes and non-diabetes groups. It was assumed that the number of deaths in the 2 groups follows binomial distribution and that the probability of death is dependent on the mean (or median) length of follow-up, under the assumption that the risk of death remains constant over the entire follow-up period.
12
. The time-dependent risk ratios were then log-transformed and pooled across all the studies using Bayesian random effects meta-analysis to produce a summary HR and 95% credible intervals (CrIs; Bayesian equivalent of CIs). The second analysis involved only those studies in which adjusted HRs or ORs and 95% CIs were reported. For these studies, additional information on covariates included in the maximally adjusted multivariable models was obtained. The subsequent maximally adjusted HRs/ORs and standard error (derived from the corresponding CIs) were logtransformed and pooled across theses studies using Bayesian random-effects meta-analysis to produce a summary HR and 95% CrIs.
The model accounts for the heterogeneity in the HRs across different study populations by assuming that the association between longterm mortality and diabetes varies from study to study. The full extent of heterogeneity in HRs was quantified using a between-study variance variable, τ (tau). Note that the pooled mean effect in a random-effects meta-analysis only represents the average of effect sizes across individual studies and may not accurately represent the effect sizes across the different study populations; therefore, to comply with best practice, 13 we also obtained the estimate of predictive mean effect and interval, which incorporates the full extent of heterogeneity in meta-analysis.
The predictive interval typically widens the uncertainty around the mean effect and thus provides a conservative but robust estimate of the true effect. Such a predictive effect and its interval can be seen as the equivalent of expected mean effect size and its variance in the outcomes, if new studies are undertaken in the future. 13 The sources of heterogeneity were assessed through subgroup analysis. provide an estimate of the number of unpublished studies and an estimate of predicted effect if all studies were available. The meta-analyses were carried out using WinBUGS. 16 The WinBUGS codes used to fit the analysis are provided in Methods S3, File S1. Publication bias assessment was carried out using STATA. Statistical significance relates to P < .05 and 95% CrIs are quoted throughout. The meta-analysis was conducted and this article prepared as per the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement (File S2).
| RESULTS
A total of 65 articles, reporting data on 66 cohorts ( 
| Studies included and patient characteristics
The detailed characteristics of the selected studies, including type and sampling structure of each study, recruitment period, number of parti- 
| Quality assessment
Based on the USPSTF quality rating criteria (Box S1, File S1), 11 43/66 studies not reporting any adjusted data for mortality risk among patients with vs without diabetes were rated as "poor" (Table S2 , File S1). In the majority of these studies, people with diabetes were older and had a higher prevalence of cardiovascular risk factors at baseline, which could have contributed to their higher mortality rates. Among the 23/66 studies reporting adjusted data, three studies adjusting analyses for key confounders (baseline difference in clinical characteristics and risk factors, acute therapies for AMI and secondary prevention therapies post AMI) and also achieving >80% follow-up as per the requirement of the USPSTF criteria were graded as "good" (Table S2 , File S1). The remaining 20 studies with adjusted data were graded as "fair" (Table S2 , File S1).
| Outcomes 3.3.1 | Diabetes and long-term mortality
From the meta-analysis of all 66 cohorts, there was evidence that long-term mortality following AMI was significantly higher among patients with diabetes compared with those without (unadjusted HR To assess for any differential effect of age or gender on mortality among those with and without diabetes, we conducted analyses using the between-group difference in mean age and mean percentage of men reported in each study as a covariate in the meta-regression.
While the risk of excess long-term mortality in the diabetes group was significantly higher in studies with older patients (interaction term 1.054 per year; 95% CrI 1.016, 1.092; P = .007) no such effect was seen in the studies with a higher proportion of men (interaction term 1.002 per percentage point; 95% CI 0.996, 1.008; P = .487).
| Assessment of publication bias and heterogeneity
There was evidence of funnel plot asymmetry (indicating possible publication bias) on visual inspection of the funnel plot for long-term mortality outcome (Figure 5 ), which was confirmed on formal testing (Egger's test t = 11.67, P ≤ .000) 14 and suggested a tendency for negative findings from small studies to remain unpublished. Adjusting for publication bias using the trim-and-fill method 15 reduced the HR to and "Diabetes" columns refer to number of deaths (numerator) and the total number of participants (denominator), respectively, in each study.
| Sensitivity analysis
In the sensitivity analysis, excluding the studies (15/66) that did not report outcome data in the suitable format, no difference in the findings of association between diabetes and long-term mortality was seen (Table S3 , File S1). Furthermore when the entire analyses were restricted to the subgroup of early survivors (42/64 studies), the association between diabetes and excess mortality was still evident Figure S1 , File S1). Further details on analyses of early survivors are provided in Results S2, Figures S1, S2
and Table S4 , File S1.
| DISCUSSION
We examined the association between diabetes and long-term mortality after AMI using a meta-analysis of all data in the post- Our findings are consistent with previous meta-analyses. In the meta-analysis of 11 trials from the TIMI group involving 62 036
Adjusted HR for long-term mortality in people with diabetes compared to those without. Follow-up time refers to mean, median or maximum duration of follow-up. The figures on the left hand side of the forest plot under the "No diabetes" and "Diabetes" columns refer to number of deaths (numerator) and the total number of participants (denominator), respectively, in each study.
patients with ACS (STEMI 46577, non-STEMI/unstable angina 15459), all-cause mortality at 1 year was 2-fold higher in patients with diabetes than in those without. 6 Another meta-analysis of 11 trials involving 6298 patients with STEMI treated with stents showed all-cause mortality at a mean of 3.3 years being 76% higher in patients with diabetes compared to those without. 7 In a more recent meta-analysis of 61 studies, assessing mortality at 6 to 12 months after index AMI or ACS, people with diabetes had 86%
higher mortality on univariate analysis compared with those without. 81 Unlike these previous meta-analyses, our findings are based on a much larger sample size and greater event numbers, and involve both unselected patients managed in real-world practice from the cohort studies, as well as selected patients managed in the highly controlled environment of RCTs. The present report confirms the findings of these previous meta-analyses and extends them to a broader group of patients with AMI followed up for a much longer period of up to 20 years. Funnel plot of the standard error of risk ratio (RR) vs RR on logarithmic scale assessing publication bias in the evidence on risk of long-term mortality in people with diabetes vs those without.
In contemporary practice, the presentation of non-STEMI is more common than STEMI, especially in those with comorbidities such as diabetes, and is associated with a similar or higher mortality rate in the longer term. 82 In the meta-analysis of TIMI trials, 6 be excluded. Our analysis is based on summary data rather than patient-level data and does not include cause-specific mortality.
The key strength of our analysis is the inclusion of a very large number of participants from across the globe from cohort studies and RCTs, with follow-up of up to 20 years, providing enough power for robust assessment of association between diabetes and long-term mortality after AMI.
In conclusion, we found that diabetes was associated with at least a 50% increase in long-term mortality after AMI, even after adjusting for confounders including demographic characteristics, comorbidities, severity of AMI and management at index admission.
Furthermore, the excess mortality in diabetes was consistent irrespective of presentation and modern treatment of AMI, persisted in the long-term after AMI and was evident in those who survived to discharge or for the first 30 days after index AMI. More research to understand mechanisms behind this excess risk and develop novel intervention is needed.
